GlobeNewswire by notified

Acarix publishes prospectus in connection with rights issue of approximately SEK 79 million

Share

Acarix publishes prospectus in connection with rights issue of approximately SEK 79 million

The Extraordinary General Meeting of Acarix AB ("Acarix" or the "Company") resolved on 23November 2021 to carry out a new share issue with preferential rights for the Company's existing shareholders at a subscription price of SEK 0.75, which may provide the Company with approximately SEK 79.3 million before deduction of cost related to the rights issue (the "Rights Issue"). The board of directors of Acarix has in connection with the Rights Issue, and prior to the subscription period which commence 1 December 2021, prepared a prospectus which today has been approved by the Swedish Financial Supervisory Authority (the "SFSA").The Rights Issue is fully guaranteed.

Publication of the prospectus

For complete information about the Rights Issue, please refer to the prospectus that has been prepared by the Company and that today has been approved by the SFSA. The prospectus is available on the Company's website (www.acarix.com) and on Redeye AB's ("Redeye") website (www.redeye.se) and will also in a couple of days be available on the SFSA's website (https://fi.se/sv/vara-register/prospektregistret/). The prospectus has only been prepared in Swedish.

The prospectus is prepared as an EU-Growth prospectus in accordance with article 15 in the Regulation (EU) 2017/1129 (the "Prospectus Regulation"). The prospectus has been approved by the SFSA, which is the Swedish competent authority in accordance with the Prospectus Regulation, in accordance with article 20 in the Prospectus Regulation. The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of Acarix or as an endorsement of the quality of the shares that are the subject of the prospectus and does not indicate that the SFSA guarantees that the facts in the prospectus are correct or complete. Investors should make their own assessment as to the suitability of investing in the Rights Issue.

Application forms will be available on the Company's and Redeye's website respectively.

Guarantee and subscription undertakings

The Rights Issue is, by way of so called bottom and top guarantees, guaranteed in full.

In addition to the guarantee commitments, certain investors, including the Company's shareholding board members as well as the CEO and CFO have provided subscription undertakings of approximately SEK 1.1 million in total, which together corresponds to approximately 1.5 percent of the Rights Issue. No commission is paid for the subscription undertakings.

Lock-up

In connection with the Rights Issue, the Company’s shareholding board members, the CEO and the CFO, as well as the shareholder SEED Capital DK II K/S, whose shareholdings as at the date of the Prospectus in aggregate corresponds to approximately 4.4 percent of the total number of shares in the Company, have, towards Redeye, undertaken not to sell their shares in Acarix before 30 May 2022.

Timetable for the Rights Issue

  • 1 - 15 December 2021 - Subscription period
  • 1 - 10 December 2021 - Trading in subscription rights
  • 1 December 2021 - Trading in BTA until the Rights Issue has been registered with the Swedish Companies Registration Office
  • 20 December 2021 - Announcement of the outcome of the Rights Issue

Investment meetings

Acarix will host a at the digital investment meeting on Thursday, 9 December 2021. Invitations to this will be presented on Redeye’s website, www.redeye.se.

Advisers

Redeye AB is acting as financial adviser and Baker McKenzie is acting as legal adviser to Acarix in connection with the Rights Issue. Hagberg & Aneborn Fondkommission AB is acting as issuing agent.

Contact person for more information

Per Persson, CEO, E-mail: per.persson@acarix.com, Phone: +46 73 600 59 90

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor® system is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 97% confidence. Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Adviser of Acarix. For more information, please visit www.acarix.com.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else. This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A prospectus, corresponding to an EU Growth Prospectus regarding the Rights Issue described in this press release, has been approved by the Swedish Financial Supervisory Authority ("SFSA") (Sw. Finansinspektionen). The Prospectus has been published by the Company on the Company's web page. The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

Redeye is acting for Acarix in connection with the Offering and no one else and will not be responsible to anyone other than Acarix for providing the protections afforded to its clients nor for giving advice in relation to the Offering or any other matter referred to herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the Unites States, Australia, Canada, Hong Kong, Japan, New Zeeland, Singapore, South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq First North Growth Market rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Acarix have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”).

Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Acarix may decline and investors could lose all or part of their investment; the shares in Acarix offer no guaranteed income and no capital protection; and an investment in the shares in Acarix is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Acarix. Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Acarix and determining appropriate distribution channels.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alation Welcomes Tim Harford OBE as Keynote Speaker at revAlation in London18.8.2022 09:00:00 CEST | Press release

World renowned behavioural economist joins The Very Group CDO to keynote Alation’s industry conference LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Alation Inc., the leader inenterprise data intelligence solutions, today announced that revAlation, its flagship industry conference for data professionals across EMEA, will take place on 4th October and 5th October at County Hall, London. The two-day event will feature data networking opportunities, data training, and keynotes from award winning economist, journalist, and broadcaster Tim Harford, and Chief Data Officer of The Very Group, Steve Pimblett. Tim Harford is a bestselling author of books about economics and data, and the writer of the award-winning Financial Times column, The Undercover Economist. Harford will keynote the event and discuss how to use data and economics in everyday life. Steve Pimblett is the Chief Data Officer at leading UK and Ireland online retailer, The Very Group. Pimblett is an experienced data professional, ha

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)18.8.2022 08:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 August 2022 at 9:30 am Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly or indirectly by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 16 August 2022 below five (5) per cent of Sampo plc’s total voting rights. Sampo's share capital comprises 533,261,351 shares, of which 533,061,351 are A shares and 200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 534,061,351. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B)Resultin

Systemair's Interim Report for the first quarter will be presented on August 2518.8.2022 08:00:00 CEST | Press release

Press Release, 18 August 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q1 for the financial year 2022/23 will be published at 13:00 CET on August 25, 2022. A telephone conference will be held at 13:30 CET on August 25, 2022. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. In order to participate in the telephone conference: Call 010-884 8016 alternative international call +44 20 3936 2999 and enter code 539199 minutes before start. The presentation will be published on group.systemair.com For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, www.systemair.com Systemair in brief Systemair is a leading ventilation company with operations in 52 countries in Europe, North America, the Middle East, Asia, Australia and Africa. The Company had sales of SEK 9.6 billion in the 2021/22 financial year and today employs approximately 6,700

Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review18.8.2022 08:00:00 CEST | Press release

The TENDU interim safety results from nine patients show no safety concernsTrial extended to enroll up to three additional patients at the highest dose levelTENDU designed to evaluate the Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer Oslo, 18August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level. The Drug Safety Monitoring Board, a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns in any of the three dose cohorts. A total of nine patients have now been treated; three at each dose level (40 mcg, 400 mcg and 960 mcg). Ultimovacs plans to enroll up to three additional patients at the highest dose level (960 mcg) pro

Systemairs rapport för det första kvartalet presenteras den 25 augusti18.8.2022 08:00:00 CEST | Pressemelding

Pressmeddelande 18 augusti 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) delårsrapport Q1 för räkenskapsåret 2022/23 kommer att offentliggöras kl. 13:00 CET den 25 augusti 2022. En telefonkonferens arrangeras kl. 13:30 CET den 25 augusti 2022. Rapporten presenteras av Roland Kasper, CEO, samt Anders Ulff, CFO. För att delta i telefonkonferensen: Ring 010-884 8016 alt. internationellt +44 20 3936 2999 och uppge kod 539199 minuter före start. Presentationen publiceras på group.systemair.com För ytterligare information kontakta: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, www.systemair.com Systemair i korthet Systemair är ett ledande ventilationsföretag med verksamhet i 52 länder i Europa, Nordamerika, Mellanöstern, Asien, Australien och Afrika. Bolaget omsatte 9,6 miljarder kronor räkenskapsåret 2021/22 och har idag cirka 6 700 anställda. Sedan grundandet av Systemair 1974 har bolaget uppvisat positiva rör